| Dose mapping after endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a single measurement after 4 days H Hänscheid, C Lapa, AK Buck, M Lassmann, RA Werner Journal of Nuclear Medicine 59 (1), 75-81, 2018 | 193 | 2018 |
| 18F-labeled, PSMA-targeted radiotracers: leveraging the advantages of radiofluorination for prostate cancer molecular imaging RA Werner, T Derlin, C Lapa, S Sheikbahaei, T Higuchi, FL Giesel, S Behr, ... Theranostics 10 (1), 1, 2020 | 170 | 2020 |
| CXCR4-directed theranostics in oncology and inflammation M Kircher, P Herhaus, M Schottelius, AK Buck, RA Werner, HJ Wester, ... Annals of nuclear medicine 32, 503-511, 2018 | 142 | 2018 |
| CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed multiple myeloma C Lapa, K Herrmann, A Schirbel, H Hänscheid, K Lückerath, ... Theranostics 7 (6), 1589, 2017 | 134 | 2017 |
| Prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer: an update on important pitfalls S Sheikhbahaei, RA Werner, LB Solnes, KJ Pienta, MG Pomper, ... Seminars in nuclear medicine 49 (4), 255-270, 2019 | 111 | 2019 |
| Imaging of myocardial inflammation with somatostatin receptor based PET/CT—a comparison to cardiac MRI C Lapa, T Reiter, X Li, RA Werner, S Samnick, R Jahns, AK Buck, G Ertl, ... International journal of cardiology 194, 44-49, 2015 | 109 | 2015 |
| Imaging of chemokine receptor 4 expression in neuroendocrine tumors-a triple tracer comparative approach RA Werner, A Weich, T Higuchi, JS Schmid, A Schirbel, M Lassmann, ... Theranostics 7 (6), 1489, 2017 | 97 | 2017 |
| CXCR4-targeted theranostics in oncology AK Buck, SE Serfling, T Lindner, H Hänscheid, A Schirbel, S Hahner, ... European Journal of Nuclear Medicine and Molecular Imaging 49 (12), 4133-4144, 2022 | 96 | 2022 |
| 68Gallium- and 90Yttrium-/177Lutetium: “theranostic twins” for diagnosis and treatment of NETs RA Werner, C Bluemel, MS Allen-Auerbach, T Higuchi, K Herrmann Annals of nuclear medicine 29, 1-7, 2015 | 95 | 2015 |
| Stroke‐induced chronic systolic dysfunction driven by sympathetic overactivity M Bieber, RA Werner, E Tanai, U Hofmann, T Higuchi, K Schuh, ... Annals of neurology 82 (5), 729-743, 2017 | 92 | 2017 |
| Pre-therapy somatostatin receptor-based heterogeneity predicts overall survival in pancreatic neuroendocrine tumor patients undergoing peptide receptor radionuclide therapy RA Werner, H Ilhan, S Lehner, L Papp, N Zsótér, I Schatka, DO Muegge, ... Molecular imaging and biology 21, 582-590, 2019 | 91 | 2019 |
| Generative adversarial networks for the creation of realistic artificial brain magnetic resonance images K Kazuhiro, RA Werner, F Toriumi, MS Javadi, MG Pomper, LB Solnes, ... Tomography 4 (4), 159, 2018 | 91 | 2018 |
| Feasibility of CXCR4-directed radioligand therapy in advanced diffuse large B-cell lymphoma C Lapa, H Hänscheid, M Kircher, A Schirbel, G Wunderlich, RA Werner, ... Journal of Nuclear Medicine 60 (1), 60-64, 2019 | 89 | 2019 |
| Somatostatin receptor based PET/CT in patients with the suspicion of cardiac sarcoidosis: an initial comparison to cardiac MRI C Lapa, T Reiter, M Kircher, A Schirbel, RA Werner, T Pelzer, C Pizarro, ... Oncotarget 7 (47), 77807, 2016 | 89 | 2016 |
| Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity RA Werner, C Lapa, H Ilhan, T Higuchi, AK Buck, S Lehner, P Bartenstein, ... Oncotarget 8 (4), 7039, 2016 | 86 | 2016 |
| A systematic review and meta-analysis of the effectiveness and toxicities of lutetium-177–labeled prostate-specific membrane antigen–targeted radioligand therapy in metastatic … MS Sadaghiani, S Sheikhbahaei, RA Werner, KJ Pienta, MG Pomper, ... European urology 80 (1), 82-94, 2021 | 84 | 2021 |
| Imaging of CXC motif chemokine receptor 4 expression in 690 patients with solid or hematologic neoplasms using 68Ga-pentixafor PET AK Buck, A Haug, N Dreher, A Lambertini, T Higuchi, C Lapa, A Weich, ... Journal of Nuclear Medicine 63 (11), 1687-1692, 2022 | 80 | 2022 |
| Retention kinetics of the 18F-labeled sympathetic nerve PET tracer LMI1195: comparison with 11C-hydroxyephedrine and 123I-MIBG RA Werner, C Rischpler, D Onthank, C Lapa, S Robinson, S Samnick, ... Journal of Nuclear Medicine 56 (9), 1429-1433, 2015 | 80 | 2015 |
| The theranostic promise for Neuroendocrine Tumors in the late 2010s-Where do we stand, where do we go? RA Werner, A Weich, M Kircher, LB Solnes, MS Javadi, T Higuchi, ... Theranostics 8 (22), 6088, 2018 | 76 | 2018 |
| Imaging inflammation in atherosclerosis with CXCR4-directed 68Ga-pentixafor PET/CT: correlation with 18F-FDG PET/CT M Kircher, J Tran-Gia, L Kemmer, X Zhang, A Schirbel, RA Werner, ... Journal of Nuclear Medicine 61 (5), 751-756, 2020 | 72 | 2020 |
